Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR55 | Q9Y2T6 | 3/20 | 0.63 |
| ▸ | CNR1 | P21554 | 2/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.63 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.63 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.54 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.43 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | STK10 | O94804 | 1/20 | 0.38 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | XBP1 | P17861 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29601316 | 1.00 | GPR55 (0.63) | GPR55CNR1HTTGPR35CHRM2 | |
| SCHEMBL23983150 | 0.95 | CNR1 (0.58) | GPR55CNR1HTTGPR35CHRM2 | |
| SCHEMBL22111803 | 0.90 | CNR1 (0.53) | GPR55CNR1HTTGPR35CHRM2 | |
| SCHEMBL22076811 | 0.90 | CNR1 (0.56) | GPR55CNR1HTTGPR35CHRM2 | |
| SCHEMBL31003652 | 0.90 | CNR1 (0.53) | GPR55CNR1HTTGPR35CHRM2 | |
| SCHEMBL23791516 | 0.90 | CNR1 (0.56) | GPR55CNR1HTTGPR35CHRM2 | |
| SCHEMBL22076820 | 0.90 | CNR1 (0.53) | GPR55CNR1HTTGPR35CHRM2 | |
| SCHEMBL22111761 | 0.90 | CNR1 (0.53) | GPR55CNR1HTTGPR35CHRM2 | |
| SCHEMBL22111890 | 0.90 | CNR1 (0.56) | GPR55CNR1HTTGPR35CHRM2 | |
| SCHEMBL31185087 | 0.89 | CNR1 (0.55) | GPR55CNR1HTTGPR35CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070299102-A1 | Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer | TOPO TARGET A/S (DK) | 2007-12-27 | — | — | US | claimed |
| US-11584718-B2 | Activators of the unfolded protein response | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2023-02-21 | — | — | US | disclosed |
| WO-2022087234-A1 | ANTICANCER COMPOUNDS SELECTIVE FOR ER-POSITIVE CANCERS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2022-04-28 | — | — | WO | disclosed |
| US-20210340100-A1 | ACTIVATORS OF THE UNFOLDED PROTEIN RESPONSE | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2021-11-04 | — | — | US | disclosed |
| US-20210276951-A1 | ACTIVATORS OF THE UNFOLDED PROTEIN RESPONSE | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2021-09-09 | — | — | US | disclosed |
| US-11046647-B2 | Activators of the unfolded protein response | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2021-06-29 | — | — | US | disclosed |
| US-20200190029-A1 | ACTIVATORS OF THE UNFOLDED PROTEIN RESPONSE | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2020-06-18 | — | — | US | disclosed |
| US-20070299102-A1 | Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer | TOPO TARGET A/S (DK) | 2007-12-27 | — | — | US | disclosed |
| EP-1734951-A2 | DIPHENYL-INDOL-2-ON COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | TopoTarget A/S (DK) | 2006-12-27 | — | — | EP | disclosed |
| WO-2005097107-A2 | DIPHENYL - INDOL-2-ON COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | TOPOTARGET A/S (DK) | 2005-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200190029-A1 | ACTIVATORS OF THE UNFOLDED PROTEIN RESPONSE | HSPA5, DDIT3, XBP1 | GPR55 2591/4885CNR1 3790/4885HTT 924/4885 |
| US-20070299102-A1 | Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer | MTOR, RICTOR, CDK4 | GPR55 2338/4885CNR1 973/4885HTT 1880/4885 |
| US-11584718-B2 | Activators of the unfolded protein response | HSPA5, DDIT3, XBP1 | GPR55 2591/4885CNR1 3790/4885HTT 924/4885 |
| US-11046647-B2 | Activators of the unfolded protein response | HSPA5, DDIT3, XBP1 | GPR55 2591/4885CNR1 3790/4885HTT 924/4885 |
| US-20210276951-A1 | ACTIVATORS OF THE UNFOLDED PROTEIN RESPONSE | HSPA5, DDIT3, XBP1 | GPR55 2591/4885CNR1 3790/4885HTT 924/4885 |
| US-20210340100-A1 | ACTIVATORS OF THE UNFOLDED PROTEIN RESPONSE | HSPA5, DDIT3, XBP1 | GPR55 2591/4885CNR1 3790/4885HTT 924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.